Navigation Links
Diabetes Drug Byetta Caused Arkansas Man’s Pancreatic Cancer and Resulting Injuries, Alleges Lawsuit Filed by Parker Waichman LLP and Co-Counsel

New York, New York (PRWEB) May 30, 2013

Parker Waichman LLP, a national law firm dedicated to protecting the rights of victims injured by defective drugs, and The Drakulich Firm, based in San Diego, have filed a lawsuit on behalf of an Arkansas man who developed pancreatic cancer and resulting injuries allegedly from using the diabetes drug Byetta. The suit was filed on May 28, 2013, in the U.S. District Court for the Southern District of California (Case No. 13-cv-99999). Amylin Pharmaceuticals LLC, Amylin Pharmaceuticals Inc. and Eli Lilly and Co. have so far been named as Defendants.

According to the Complaint, the Plaintiff was prescribed and injected Byetta to treat his diabetes beginning around 2007 and continued using it at least until June 2012. On or about Feb. 25, 2013, a CT scan determined that the Plaintiff had pancreatic adenocarcinoma, the most common form of pancreatic cancer. Once diagnosed, the Plaintiff began treatment, which included chemotherapy and radiation therapy. He went on to develop jaundice.

The Complaint alleges that the Defendants knew or should have known that Byetta caused serious side effects, yet they continued to market and sell the drug by providing false and misleading information. The suit seeks damages for extensive pain and suffering, and severe emotional distress, among other things.

Byetta was approved by the U.S. Food Drug Administration (FDA) in 2005. It falls into a class of drugs called incretin mimetics, which work by mimicking the incretin hormones that the body usually naturally produces to stimulate the release of insulin after a meal. The drugs are used along with diet and exercise to lower blood sugar in adults with type 2 diabetes.

The Institute for Safe Medication Practices (ISMP) revealed in its most recent QuarterWatch report that glucagon-like peptide-1 (GLP-1) agents – such as Byetta, Victoza, Januvia, Onglyza (saxagliptin) and Tradjenta (linagliptin) – are 25 times more likely to be linked to pancreatic cancer. The report, issued on April 18th, used information from the FDA’s adverse event report database to analyze a year’s worth of reports related to the type 2 diabetes drugs. ISMP found that there were 105 cases of pancreatic cancer linked to these medications, compared to a different class of diabetes drugs; 71 of those cases were associated with Byetta. The watchdog group also found that injectable incretin mimetics were 28 times more likely to be associated with pancreatitis, or inflammation of the pancreas, while oral agents were 20 times more likely to lead to the condition.

On March 14, 2013, the FDA announced that it was investigating incretin mimetic drugs after researchers found evidence of pancreatitis and pre-cancerous cell changes known as pancreatic duct metaplasia. According to the FDA, incretin mimetic drugs include: exenatide (Byetta, Bydureon), liraglutide (Victoza), sitagliptin (Januvia, Janumet, Janumet XR, Juvisync), saxagliptin (Onglyza, Kombiglyze XR), alogliptin (Nesina, Kazano, Oseni), and linagliptin (Tradjenta, Jentadueto).

Parker Waichman LLP continues to offer free legal consultations to victims of alleged Byetta injuries, including bladder cancer, heart problems, and eye injuries. If you or a loved one were diagnosed with bladder cancer after taking Byetta, please contact their office by visiting Free case evaluations are also available by calling 1-800-LAW-INFO (1-800-529-4636).

Parker Waichman LLP
Gary Falkowitz, Managing Attorney
(800) LAW-INFO
(800) 529-4636

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. How a cancer drug leads to diabetes
2. Heart failure patients with diabetes may benefit from higher glucose levels
3. Disrupted Sleep May Raise Risk for Obesity, Diabetes: Study
4. Mouse Study Hints at New Path for Diabetes Treatment
5. Common Plastics Chemical Might Boost Diabetes Risk
6. Weight-Loss Surgery Beat Drugs for Cutting Diabetes in Very Obese
7. Naturopathic care can improve blood sugar, mood in diabetes
8. Cellular pathway linked to diabetes, heart disease
9. Diabetes Groups Issue New Guidelines on Blood Sugar
10. Value of Metformin, Insulin Combo for Type 2 Diabetes Questioned
11. Xenotransplantation as a therapy for type 1 diabetes
Post Your Comments:
(Date:11/26/2015)... ... November 26, 2015 , ... Health-E-minds ... collaborated with Women’s Web – an online resource for Indian women looking ... and emotional well-being relationship, life balance, stress, professional development, and lifestyle. Health-E-minds ...
(Date:11/25/2015)... ... 25, 2015 , ... The holiday season is jam-packed with ... palates of attendees is of the utmost importance. Whether you are cooking at ... these recipes a try this holiday season. , Turkey Croquettes , ...
(Date:11/25/2015)... ... November 25, 2015 , ... Dr. John Pierce, Medical Director at the Ageless ... treatment with the Capillus272™ Pro laser therapy cap. FDA cleared for safety and efficacy, ... without the need for surgery, prescription pills, or topical foams. , “Capillus272™ Pro ...
(Date:11/25/2015)... ... 25, 2015 , ... According to an article published November 10th ... widely heralded as a breakthrough for performing hernia repairs. The article explains that the ... is that it can greatly reduce the pain that a patient might otherwise experience ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... athletic programs, launches new Wimbledon Athletics Facebook page to educate the ... for unsuspected cardiac abnormalities. About 2,000 people under the age of 25 die ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... Nov. 26, 2015 Research and Markets ( ... "Advanced Wound Care Market by Type (Dressings, Therapy Devices, ... (In-Patient Facility, Out-Patient Facility), and Geography - Global Forecast ... --> --> The purpose ... and forecast of the global advanced wound care market. ...
(Date:11/26/2015)... India , November 26, 2015 ... --> adds ... Report" and "Investigation Report on China ... and 2021 forecasts data and information ... . ...
(Date:11/26/2015)... , Nov. 26, 2015 Research ... addition of the "2016 Future Horizons and ... (TDM) Market: Supplier Shares, Country Segment Forecasts, Competitive ... --> --> ... analysis of the Italian therapeutic drug monitoring market, ...
Breaking Medicine Technology: